Matt Seeland, former Associate Product Director for the Xolair division of Novartis, talks about the long-term Xolair medical findings in asthma patients.

Xolair is a premier anti-inflammatory agent that has provided relief to countless individuals across the globe.
Xolair is a premier anti-inflammatory agent that has provided relief to countless individuals across the globe.

(Newswire.net — April 14, 2017) Sparta, New Jersey — Hailed as the world’s first biologic drug approved to treat asthma in patients, Xolair has also been in the news for its efficacy. Matt Seeland, a pharmaceutical sales expert who served as the Associate Product Director for Novartis and its Xolair division, recently discussed favorable findings of a long-term patient study. The results were reported at the annual meeting of the American Academy of Allergy, Asthma, and Immunology (AAAAI). In the 48-month observation registration of asthma patients, the drug had led to improved health with fewer asthma attacks. “Xolair performed admirably in many clinical trials before release,” says Matt, who currently works as the Director of Strategic Initiatives for Novartis. “Now, the results of this study reinforce the overall effectiveness of the drug.” To learn more about the observational study, visit http://www.healio.com/family-medicine/allergy-asthma-immunology/news/online/%7B7a607c65-19cc-4a9c-985d-bb5e3ce41b8a%7D/patients-with-asthma-see-improvement-from-xolair.

Xolair (omalizumab) is an anti-inflammatory agent. The biologic drug reached the market in 2003 after many years of positive clinical trials by Novartis. It works as an antibody, helping to decrease allergic responses in patients with asthma. It is delivered in an injection every two to four weeks by medical professionals. Participants in the U.S. based multicenter observational registration were aged 12 years or older and consisted of both male and female asthma sufferers, totaling 806 participants. In the study, the incidence of asthma exacerbations (attacks) dropped dramatically; 19% of study participants reported two or more exacerbations, while 4% reported one or more. This is in stark contrast to the levels recorded by patients prior to administration of the drug. Prior to the observational study, 61% of study participants reported two or more exacerbations and 22% reported one or more. Observational studies like these are used to supplement the findings of clinical trials. This particular study was billed as the first-ever data collected on the efficacy of asthma-treating biologics.

Matthew Seeland has worked in the pharmaceutical industry for over 25 years. He has been responsible for many roles at Novartis, including the product launch of several medications and extensive sales and marketing of products. In his free time, Matt volunteers with the Liquid Church in New Jersey. For more information about a special event, he helped orchestrate for the church, visit https://newswire.net/newsroom/pr/00095561-matthew-seeland-special-needs-program-liquid-church.html.

About Matthew Seeland

Business professional and corporate leader Matt Seeland has spent the bulk of his successful career as a pharmaceutical sales expert. He has worked with Novartis Pharmaceuticals for the past 25 years. In that time, Matt has been responsible for several successful product launches and billions of dollars in sales. When he is not innovating in marketing strategies or exceeding lofty sales goals, he works with special needs children and young adults at Liquid Church in Morristown, New Jersey.

Matthew Seeland

4 Forest Hill Drive
Sparta, New Jersey 07871
United States
(862) 432-3516
mattseeland@gmail.com
http://https:/www.linkedin.com/in/matthewseeland/
Source: http://newswire.net/newsroom/pr/00095995-matthew-seeland-special-needs-program-liquid-church.html